Combined ultrasound-antibiotic treatment of biofilms

生物膜的超声-抗生素联合治疗

• 批准号: 452083-2013
• 负责人: Wolfaardt, Gideon
• 金额: $ 1.82万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=540652
• 关键词: Combined; ultrasound; antibiotic; treatment; biofilms

Biofilms contribute to more than 65% of all bacterial infections in humans, play a significant role in harboring pathogens that cause nosocomial infections, and are extremely difficult to eradicate because they provide protection to microbial cells through a number of mechanisms. Furthermore, because of antimicrobial resistance (a phenomenon that most probably is enhanced by biofilms), new strategies to improve the efficacy of available antibiotics are critically needed. Ultrasound-microbubble (USMB) technology, a focus of our industrial partner, has been shown to improve drug-based treatments. Our research group has developed a number of experimental systems to study biofilm behavior in real time, including response to antibiotic treatment. The objective of the proposed collaboration is to evaluate the potential synergy between USMB and antibiotic treatment to eradicate biofilms, and to refine optimum levels of exposure for maximum effect.

生物膜占人类所有细菌感染的65%以上，在容纳导致医院感染的病原体方面发挥着重要作用，而且极难根除，因为它们通过多种机制为微生物细胞提供保护。此外，由于抗菌素耐药性(生物被膜很可能增强了这一现象)，迫切需要新的战略来提高现有抗生素的疗效。超声-微泡(USMB)技术是我们工业合作伙伴的重点，已被证明可以改进基于药物的治疗。我们的研究小组已经开发了一些实验系统来实时研究生物膜的行为，包括对抗生素治疗的反应。拟议合作的目标是评估USMB和抗生素治疗之间的潜在协同作用，以根除生物被膜，并改进最佳暴露水平，以实现最大效果。